Hyderabad: India is emerging as a global research hub for diabetes, genetic disorders and next-generation healthcare solutions. Union Minister Dr. Jitendra Singh said over a dozen diabetes research projects are underway under the Ministry of Science and Technology. Most are being implemented through the Department of Biotechnology (DBT), while some involve the Council of Scientific and Industrial Research (CSIR).
Speaking on November 20, he said these projects focus on molecular and genetic approaches to diabetes prevention and treatment. He also stressed that preventing obesity and diabetes among young Indians is a national responsibility. The challenge, he said, requires action beyond the medical community.
Dr. Singh made the remarks at the inaugural ceremony of RSSDI 2026 in Bengaluru. The conference is being held from November 19–22 and brings together diabetologists, clinicians, researchers and healthcare professionals from India and abroad. Shri Krishna Byre Gowda, Karnataka Minister for Greater Bengaluru Development and Parliamentary Affairs, and Dr. C. N. Manjunath, Member of Parliament, attended the event. The programme also featured fellowship distribution, award recognitions and book and guideline launches.
The Minister said India’s scientific capabilities have expanded significantly. The country has moved from relying on external solutions to developing indigenous vaccines, therapies, antibiotics and advanced medical technologies. He cited India’s DNA-based COVID-19 vaccine, indigenous antibiotics, genetic therapy research, biosimilars and the India Genome Study. He also highlighted vaccine development for HPV, dengue and malaria.
According to Dr. Singh, precision medicine and molecular-level research are creating new opportunities to understand Type 2 diabetes and related metabolic disorders. These approaches could also strengthen prevention, particularly among younger people. He called for closer collaboration among government research institutions, private researchers, clinicians, startups and medical associations. Furthermore, he stressed the importance of translational research and public-private partnerships in turning scientific findings into practical treatments.
Major studies explore new diabetes treatment approaches
One major initiative is an Indo-Danish study examining gut microbiota changes among Indian patients with prediabetes and diabetes. The research aims to improve understanding of how gut microbial patterns influence metabolic disorders. Another DBT-supported project involves genetically engineered E. coli Nissle 1917 that can produce GLP-1. Researchers are examining its potential as a probiotic-based method to deliver therapeutic molecules through the gastrointestinal tract. Human studies are expected to be undertaken.
Research at BRIC-THSTI is also examining the expression of GLP-1 analogues in gut-associated bacteria. The work aims to explore alternative ways of delivering GLP-1-based therapies. Together, these projects reflect the growing focus on molecular and biological approaches to diabetes treatment.
Other studies are examining interventions from preconception to early childhood to reduce cardiometabolic risks. These include childhood blood glucose, blood pressure and adiposity. The Minister also referred to the EINSTEIN study underway in rural Mysuru. In addition, researchers are studying how maternal nutrition during pregnancy affects the metabolic health of offspring across generations. These projects could provide evidence to strengthen preventive healthcare from early life.
Dr. Singh also highlighted research combining exosomal profiling and metabolomics. The work seeks biomarkers that could predict Type 2 diabetes among women with a history of gestational diabetes. Other studies examine links between Type 2 diabetes and metabolic dysfunction-associated fatty liver disease (MAFLD). These include research into the S100A6 pathway and a potential neutralising monoclonal antibody.
Researchers are also studying hyperinsulinemia, hepatic SIRT1 and systemic insulin resistance. Other projects examine ribosomal proteins and insulin signalling. Meanwhile, research into arachidonic acid is exploring its potential to improve glucose regulation and protect skeletal muscle from diabetes-related atrophy.
The Minister cited emerging research on macrophage Gi signalling as a possible therapeutic target for obesity and Type 2 diabetes. Findings from this research appeared in the Journal of Clinical Investigation in September 2026. He also referred to efforts to develop temperature-resilient insulin, which could ease storage and transportation. Startups are additionally exploring oral insulin. These efforts highlight the role of institutional support, technology development and risk-taking in healthcare innovation.
India has also advanced its indigenous biosimilar capabilities. Dr. Singh cited developments involving liraglutide and insulin Lispro. Such work could strengthen the country’s capacity to support affordable diabetes treatment.
The Minister said India’s population diversity, genomic research capabilities and expanding scientific infrastructure offer significant opportunities for medical research. He referred to the India Genome Study, which involves 10,000 individuals across 84 population groups. This genetic diversity, he said, can support precision medicine and contribute to global healthcare research.
Dr. Singh urged medical professionals and scientists to counter misinformation about diabetes, obesity, nutrition and weight-loss treatments. He warned against misleading diet advice from self-styled nutritionists and unscientific health claims. He also cautioned against using obesity medicines without medical prescriptions. Such misinformation, he said, can cause greater harm than a lack of information.
He called on credible scientific voices to engage actively with the public. Health decisions, he stressed, must rely on evidence and responsible medical advice. Therefore, researchers and healthcare professionals have an important role in correcting false claims.
Dr. Singh said India’s ambition to achieve Viksit Bharat by 2047 makes youth health a national priority. Nearly 70 per cent of the country’s population is below the age of 40. Protecting their health, energy and productive potential is essential, he said. Preventing obesity and diabetes among young Indians must involve scientific institutions, medical professionals, policymakers and society.
He encouraged RSSDI and the wider medical research community to engage more closely with India’s scientific initiatives. He also called for stronger research partnerships and the development of preventive, affordable and next-generation healthcare solutions. India’s progress in diabetes and metabolic health, he said, can contribute to the broader goal of building Viksit Bharat.